Daniel C. Norvell

Daniel C. Norvell

Auto-generated profile, based on publicly available information

Daniel C. Norvell

Center for Limb Loss and MoBility (CLiMB), VA Puget Sound Health Care System, Seattle, Washington

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2019 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
DNDaniel C. Norvell
Daniel C. Norvell
WLWilliam R. Ledoux
William R. Ledoux
JSJane B. Shofer
Jane B. Shofer
SHSigvard T. Hansen
Sigvard T. Hansen
JDJames Davitt
James Davitt
BSBruce J. Sangeorzan
Bruce J. Sangeorzan
Background: Newer designs and techniques of total ankle arthroplasty (TAA) have challenged the assumption of ankle arthrodesis (AA) as the primary treatment for end-stage ankle arthritis. The objective of this study was to compare physical and mental function, ankle-specific function, pain intensity, and rates of revision surgery and minor complications between these 2 procedures and to explore heterogeneous treatment effects due to age, body mass index (BMI), patient sex, comorbidities, and employment on patients treated by 1 of these 2 methods. Methods: This was a multisite prospective cohort study comparing outcomes of surgical treatment of ankle arthritis. Subjects who presented after nonoperative management had failed received either TAA or AA using standard-of-treatment care and rehabilitation. Outcomes included the Foot and Ankle Ability Measure (FAAM), Short Form-36 (SF-36) Physical and Mental Component Summary (PCS and MCS) scores, pain, ankle-related adverse events, and treatment success. Results: Five hundred and seventeen participants underwent surgery and completed a baseline assessment. At 24 months, the mean improvement in FAAM activities of daily living (ADL) and SF-36 PCS scores was significantly greater in the TAA group than in the AA group, with a difference between groups of 9 points (95% confidence interval [CI] = 3, 15) and 4 points (95% CI = 1, 7), respectively. The crude incidence risks of revision surgery and complications were greater in the AA group; however, these differences were no longer significant after adjusting for age, sex, BMI, and Functional Comorbidity Index (FCI). The treatment success rate was greater after TAA than after AA for those with an FCI of 4 (80% versus 62%) and not fully employed (81% versus 58%) but similar for those with an FCI score of 2 (81% versus 77%) and full-time employment (79% versus 78%). Conclusions: At 2-year follow-up, both AA and TAA were effective. Improvement in several patient-reported outcomes was greater after TAA than after AA, without a significant difference in the rates of revision surgery and complications. Level of Evidence: Therapeutic Level II. See Instructions for Authors for a complete description of levels of evidence.

28 May 2019 in British Journal of Surgery
Verified
Journal Article
Closed access
PDF file
JCJ. M. Czerniecki
J. M. Czerniecki
MTM. L. Thompson
M. L. Thompson
ALA. J. Littman
A. J. Littman
EBE. J. Boyko
E. J. Boyko
GLG. J. Landry
G. J. Landry
DND. C. Norvell
D. C. Norvell

1 October 2012 in Archives of Physical Medicine and Rehabilitation
Verified
Journal Article
Closed access
JCJoseph M. Czerniecki
Joseph M. Czerniecki
ATAaron P. Turner
Aaron P. Turner
RWRhonda M. Williams
Rhonda M. Williams
KHKevin N. Hakimi
Kevin N. Hakimi
DNDaniel C. Norvell
Daniel C. Norvell

1 October 2020 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
DNDaniel C. Norvell
Daniel C. Norvell
JCJoseph M. Czerniecki
Joseph M. Czerniecki

1 January 2017 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
JCJoseph M. Czerniecki
Joseph M. Czerniecki
ATAaron P. Turner
Aaron P. Turner
RWRhonda M. Williams
Rhonda M. Williams
MTMary Lou Thompson
Mary Lou Thompson
GLGreg Landry
Greg Landry
DNDaniel C. Norvell
Daniel C. Norvell

13 March 2019 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
DND. C. Norvell
D. C. Norvell
MTM. L. Thompson
M. L. Thompson
EBE. J. Boyko
E. J. Boyko
GLG. Landry
G. Landry
ALA. J. Littman
A. J. Littman
JCJ. M. Czerniecki
J. M. Czerniecki
Background: Patients who undergo lower extremity amputation secondary to the complications of diabetes or peripheral artery disease have poor long-term survival. Providing patients and surgeons with individual-patient, rather than population, survival estimates provides them with important information to make individualized treatment decisions. Methods: Patients with peripheral artery disease and/or diabetes undergoing their first unilateral transmetatarsal, transtibial or transfemoral amputation were identified in the Veterans Affairs Surgical Quality Improvement Program (VASQIP) database. Stepdown logistic regression was used to develop a 1-year mortality risk prediction model from a list of 33 candidate predictors using data from three of five Department of Veterans Affairs national geographical regions. External geographical validation was performed using data from the remaining two regions. Calibration and discrimination were assessed in the development and validation samples. Results: The development sample included 5028 patients and the validation sample 2140. The final mortality prediction model (AMPREDICT-Mortality) included amputation level, age, BMI, race, functional status, congestive heart failure, dialysis, blood urea nitrogen level, and white blood cell and platelet counts. The model fit in the validation sample was good. The area under the receiver operating characteristic (ROC) curve for the validation sample was 0·76 and Cox calibration regression indicated excellent calibration (slope 0·96, 95 per cent c.i. 0·85 to 1·06; intercept 0·02, 95 per cent c.i. –0·12 to 0·17). Given the external validation characteristics, the development and validation samples were combined, giving a total sample of 7168. Conclusion: The AMPREDICT-Mortality prediction model is a validated parsimonious model that can be used to inform the 1-year mortality risk following non-traumatic lower extremity amputation of patients with peripheral artery disease or diabetes.